טיאסר 100 מ"ג
bioavenir ltd - losartan as potassium 100 mg - tablets - losartan - hypertension: losartan is indicated for the treatment of heart failure ( nyha ii and iii) usually in addition to diuretics and/or digitalis if use of an ace inhibitor is not appropriate. switching patients with heart failure who are stable on an ace inhibitor to tiasar is not recommended. renal protection in type - 2 diabetic patients with proteinuria: losartan is indicated to delay the progression of renal disease as measured by a reduction in the combined incidence of doubling of serum creatinine end stage renal disease ( need for dialysis or renal transplantation) or death and to reduce proteinuria. reduction in the risk of cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrphy. losartan is indicated to reduce the risk of cardiovascular morbidity and mortality as measured by the combined incidence of cardiovascular death stroke and myocardial infarction in hypertensive patients with left ventricular hypertrphy. the benefit of tiasar on the primary deposite end poin
סטאבניר
bioavenir ltd - pravastatin sodium 40 mg - tablets - pravastatin - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa
צפוראקס 250
bioavenir ltd - cefuroxime as axetil 250 mg - film coated tablets - cefuroxime - treatment of infections caused by micro-organisms susceptible to cefuroxime.
צפוראקס 250
bioavenir ltd - cefuroxime as axetil 250 mg - film coated tablets - cefuroxime - treatment of infections caused by micro-organisms susceptible to cefuroxime.
צפוראקס 500
bioavenir ltd - cefuroxime as axetil 500 mg - film coated tablets - cefuroxime - treatment of infections caused by micro-organisms susceptible to cefuroxime.
צפוראקס 500
bioavenir ltd - cefuroxime as axetil 500 mg - film coated tablets - cefuroxime - treatment of infections caused by micro-organisms susceptible to cefuroxime.
גמניל 200 מ"ג
bioavenir ltd - gemcitabine 200 mg/vial - powder for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
גמניל 1000 מ"ג
bioavenir ltd - gemcitabine 1000 mg/vial - powder for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy.prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.
custodiol - htk solution
bioavenir - רופא - תמיסה לאיחסון איברים לפני השתלה
אמפיסולבניר 1.5 גר'
bioavenir ltd - ampicillin as sodium salt; sulbactam as sodium salt - אבקה להכנת תמיסה לזריקה - ampicillin as sodium salt 1000 mg; sulbactam as sodium salt 500 mg - sulbactam